| [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. | |
| | |
MedLine Citation:
|
PMID: 19234708 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate [(11)C]choline positron emission tomography/computed tomography ([(11)C]choline PET/CT) for the detection of a biochemical recurrence of prostate cancer after radical prostatectomy. METHODS: Retrospective analysis of [(11)C]choline PET/CT performed in 41 consecutive prostate cancer patients with a rising PSA. The mean time to biochemical relapse was 24 months. PSA levels were determined at time of examination, and patients received either a targeted biopsy or surgery. Histopathology reports served as reference for the evaluation of the [(11)C]choline PET/CT findings. RESULTS: Mean PSA in [(11)C]choline PET/CT positive patients was 3.1 ng/ml (median 2.2 ng/ml, range 0.5-11.6 ng/ml) and 0.86 ng/ml in [(11)C]choline PET/CT negative patients (median 0.83 ng/ml, range 0.41-1.40 ng/ml). Six of 12 patients with PSA < 1.5 ng/ml [(11)C]choline PET/CT revealed a pathological uptake. Histopathology was positive in 6/12 patients in this group. At PSA levels ranging from 1.5 to 2.5 ng/ml all [(11)C]choline PET/CT were positive (n = 16), a positive histology was found in 12/16 patients (75%) and at PSA 2.5-5 ng/ml [(11)C]choline PET/CT was positive in 8/8 patients, confirmed by histology in 7/8 patients. Finally, at PSA higher than 5 ng/ml [(11)C]choline PET/CT identified 5/5 patients positive all confirmed by histology. The sensitivity of [(11)C]choline PET/CT for the detection of recurrence at PSA < 2.5 ng/ml was 89% with a positive predictive value of 72%. CONCLUSION: [(11)C]choline PET/CT is useful for re-staging of prostate cancer in patients with rising PSA even at levels below 1.5 ng/ml. Our study confirms results from other published studies on [(11)C]choline PET/CT in prostate cancer relapse. |
| | |
Authors:
|
Ludwig Rinnab; Joerg Simon; Richard E Hautmann; M V Cronauer; Kathrin Hohl; Andreas K Buck; Sven N Reske; Felix M Mottaghy |
Related Documents
:
|
9605668 - Effectiveness of positron emission tomography for the detection of melanoma metastases. 19707528 - Clinical applications of fdg pet and pet/ct in head and neck cancer. 10586018 - Endosonography in decision making and management of gastrointestinal endocrine tumors. 19293768 - The evolving role of pet-ct in the management of esophageal cancer. 19299488 - C-arm ct measurement of cerebral blood volume: an experimental study in canines. 11910328 - Advanced magnetic resonance imaging techniques for patients with hemifacial spasm. |
Publication Detail:
|
Type: Journal Article Date: 2009-02-21 |
Journal Detail:
|
Title: World journal of urology Volume: 27 ISSN: 1433-8726 ISO Abbreviation: World J Urol Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-09-25 Completed Date: 2009-12-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8307716 Medline TA: World J Urol Country: Germany |
Other Details:
|
Languages: eng Pagination: 619-25 Citation Subset: IM |
Affiliation:
|
Department of Urology, University of Ulm, Ulm, Germany. ludwig.rinnab@uniklinik-ulm.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Choline / analogs & derivatives*, diagnostic use Humans Male Middle Aged Neoplasm Recurrence, Local / blood, diagnosis* Positron-Emission Tomography* Prostate-Specific Antigen / blood Prostatectomy* Prostatic Neoplasms / blood, diagnosis* Retrospective Studies Tomography, X-Ray Computed* |
| Chemical | |
Reg. No./Substance:
|
0/methyl carbon-11 choline; 62-49-7/Choline; EC 3.4.21.77/Prostate-Specific Antigen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Updates in intravesical electromotive drug administration((R)) of mitomycin-C for non-muscle invasiv...
Next Document: No evidence for melatonin-linked immunoenhancement over the annual cycle of an avian species.